Luca Gianni
Impact in
- Oncology top 0.01%
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Peptidase Inhibition and Analysis
- Cancer Research top 0.05%
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
Papers in
- Oncology 250
- Cancer Treatment and Pharmacology 124
- HER2/EGFR in Cancer Research 108
-
- Breast Cancer Treatment Studies 64
- Cancer Genomics and Diagnostics 29
- Co-authors
- Giampaolo BianchiniGiorgio MinottiEmanuela SalvatorelliPierantonio MennaGaetano CairoMelinda E. SandersIngrid A. MayerJustin M. Balko
- Journals
- Journal of Clinical Oncology (75 papers)Annals of Oncology (46 papers)Cancer Research (19 papers)European Journal of Cancer (13 papers)The Lancet Oncology (7 papers)
- Partner nations
- ItalyUnited StatesSpain
In The Last Decade
Luca Gianni
306 papers receiving 30.0k citations
Hit Papers
Peers
Comparison fields: 5 of 159
- Oncology 20.5k
- Cancer Research 8.3k
- Radiology, Nuclear Medicine and Imaging 5.7k
- Pulmonary and Respiratory Medicine 6.0k
- Cardiology and Cardiovascular Medicine 3.4k
Countries citing papers authored by Luca Gianni
This map shows the geographic impact of Luca Gianni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luca Gianni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luca Gianni more than expected).
Fields of papers citing papers by Luca Gianni
This network shows the impact of papers produced by Luca Gianni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luca Gianni. The network helps show where Luca Gianni may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Luca Gianni, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2024 | 9 | |
| 2 | 2023 | 10 | |
| 3 | Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple-negative, early high-risk and locally advanced breast cancer: NeoTRIP Michelangelo randomized study Hit paper breakdown → | 2022 | 204 |
| 4 | 2022 | 37 | |
| 5 | 2021 | 12 | |
| 6 | 2018 | 9 | |
| 7 | 2017 | 25 | |
| 8 | 11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial Hit paper breakdown → | 2017 | 688 |
| 9 | 2017 | 1 | |
| 10 | 2016 | 86 | |
| 11 | 2014 | 44 | |
| 12 | 2013 | 199 | |
| 13 | 2013 | 30 | |
| 14 | Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer Hit paper breakdown → | 2012 | 2665 |
| 15 | 2012 | 21 | |
| 16 | Triple-Negative Breast Cancer: An Unmet Medical Need Hit paper breakdown → | 2011 | 629 |
| 17 | 2010 | 53 | |
| 18 | 2008 | 66 | |
| 19 | Anthracyclines: Molecular Advances and Pharmacologic Developments in Antitumor Activity and Cardiotoxicity Hit paper breakdown → | 2004 | 3006 |
| 20 | Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. | 2003 | 41 |
About Luca Gianni
Luca Gianni is a scholar working on Oncology, Cancer Research, Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Biophysics, having authored 309 papers that have together received 30.7k indexed citations. Recurring topics across this work include Cancer Treatment and Pharmacology (124 papers), HER2/EGFR in Cancer Research (108 papers), Breast Cancer Treatment Studies (64 papers), Monoclonal and Polyclonal Antibodies Research (43 papers), Advanced Breast Cancer Therapies (40 papers), Cancer Genomics and Diagnostics (29 papers), Chemotherapy-induced cardiotoxicity and mitigation (27 papers) and Lung Cancer Treatments and Mutations (25 papers). The work is most often cited by research in Oncology (20.5k citations), Cancer Research (8.3k citations), Radiology, Nuclear Medicine and Imaging (5.7k citations), Pulmonary and Respiratory Medicine (6.0k citations) and Cardiology and Cardiovascular Medicine (3.4k citations). Luca Gianni has collaborated with scholars based in Italy, United States and Spain. Frequent co-authors include Giampaolo Bianchini, Giorgio Minotti, Emanuela Salvatorelli, Pierantonio Menna, Gaetano Cairo, Melinda E. Sanders, Ingrid A. Mayer, Justin M. Balko, José Baselga and Sibylle Loibl. Their work appears in journals such as Journal of Clinical Oncology, Annals of Oncology, Cancer Research, European Journal of Cancer and The Lancet Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.